Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis (Q27012696)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis	scientific article

Statements

scholarly article

1 reference

2 references

15 December 2019

4 February 2021

systematic review

1 reference

1 reference

Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis (English)

0 references

type 2 diabetes

2 references

15 December 2019

4 February 2021

GPCR, family 2, glucagon receptor

1 reference

31 July 2019

1 reference

18 October 2019

glucagon-like peptide-1

1 reference

20 November 2019

1 reference

15 December 2019

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Sanbao Chai

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Lishi Li

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Kai Yu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Zhirong Yang

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Shanshan Wu

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Yuan Zhang

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Linong Ji

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Siyan Zhan

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

publication date

2015

1 reference

20 January 2015

9 references

13 March 2019

14 March 2019

24 March 2019

31 July 2019

18 October 2019

17 November 2019

20 November 2019

15 December 2019

4 February 2021

Journal of Diabetes Research

11 references

13 March 2019

14 March 2019

24 March 2019

31 July 2019

18 October 2019

17 November 2019

20 November 2019

15 December 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

4 February 2021

2015

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

157201

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

copyright license

Creative Commons Attribution 3.0 Unported

9 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

14 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

31 July 2019

Europe PubMed Central

18 October 2019

Europe PubMed Central

17 November 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

15 December 2019

Europe PubMed Central

4 February 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Mechanisms of action of glucagon-like peptide 1 in the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Medical Consequences of Obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

https://api.crossref.org/works/10.1155%2F2015%2F157201

22 April 2017

The Physiology of Glucagon-like Peptide 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

21 March 2017

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

7 April 2017

Automating network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Glucagon-like peptide-1 receptor agonists and their effects on weight reduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Graphical tools for network meta-analysis in STATA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Evaluation of inconsistency in networks of interventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

GLP-1 based therapies: differential effects on fasting and postprandial glucose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

Obesity and type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

28 September 2017

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4320855

31 May 2018

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F157201

21 January 2018

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F157201

21 January 2018

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F157201

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F157201

21 January 2018

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F157201

21 January 2018

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25688373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2015/157201

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

release_zj5fjj4obvdypkbpblu3vsdb4q

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25688373%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27012696&oldid=2037255198"